Contract analysis

I. Executive Summary On October 12, 2023, the Internal Revenue Service, Large Business & International Division, Exam Team LB&I-NE-TP-2022-00641, issued a Notice of Proposed Adjustment ("NOPA") to Penterra Pharmaceuticals Corp. ("PPC" or the "Company") for tax years 2017, 2018, 2019, and 2020, proposing net transfer pricing adjustments under Internal Revenue Code ("IRC") § 482 totaling $380,400,000. The NOPA is the c

II. Background A. Penterra's Corporate Structure and IP Arrangement Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation that is publicly traded on the Nasdaq Stock Market under the ticker symbol "PPCA." PPC's principal executive offices are located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. For fiscal year 2020, PPC reported consolidated revenue of approximately $6.82 billion a

III. Detailed Analysis of NOPA Proposed Adjustments A. Adjustment Category 1: CSA Cost-Sharing Ratio — $235,010,000

1. IRS Position The first and largest category of proposed adjustments relates to the CSA cost-sharing ratios for tax years 2017 through 2020. The IRS asserts that PBI's cost-sharing percentages, as determined by PPC's contemporaneous documentation, understated PBI's share of reasonably anticipated benefits from the covered intangibles, thereby understating PPC's U.S.-source income under the CSA and resulting in an u

2. Legal Framework The legal framework governing the CSA adjustments implicates several provisions of the Internal Revenue Code and Treasury Regulations: IRC § 482 authorizes the Secretary to distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among two or more organizations, trades, or businesses owned or controlled directly or indirectly by the same interests, if the Secre

3. Analysis of IRS Vulnerabilities — CSA Adjustments Our analysis identifies several significant vulnerabilities in the IRS's position on the CSA cost-sharing adjustments, each of which should be developed in the Protest and any subsequent Appeals proceedings. Reasonably Anticipated Benefits Methodology and Hindsight Bias. The most fundamental vulnerability in the IRS's CSA position is the apparent use of hindsight-i

1. IRS Position The second category of proposed adjustments relates to the royalty rate under PBI's license of pre-2012 vintage compounds from PPC. The IRS proposes increasing the royalty rate from 4.5% of net sales to 11.0% of net sales, based on the IRS's analysis of comparable uncontrolled transaction ("CUT") data from third-party pharmaceutical licensing agreements that the IRS contends support a higher arm's-len

2. Legal Framework The legal framework governing the royalty rate adjustments is set forth principally in the following regulatory provisions: Treas. Reg. § 1.482-4 provides methods for determining the arm's-length consideration for the transfer of intangible property (or the use of intangible property through a license), including the comparable uncontrolled transaction method, the comparable profits method, and the

3. Analysis of IRS Vulnerabilities — Royalty Rate Adjustments Our analysis identifies several critical vulnerabilities in the IRS's royalty rate position, which collectively present a strong basis for contesting the proposed adjustment. IRS CUT Selection Criteria Are Overly Aggressive. The IRS's CUT analysis relies on a set of comparable license agreements that, upon initial review, appear to involve early-stage, hig

IV. Analysis of IRS Economic Substance Challenge A. IRS's DEMPE Argument In addition to the specific transfer pricing adjustments discussed in Section III, the IRS asserted, as a supplemental basis for its proposed adjustments, that PBI lacked sufficient economic substance to justify its role as IP owner and CSA participant. The IRS's argument is framed in the language of the OECD's DEMPE framework — Development, Enh

V. Analysis of Proposed Penalty — IRC § 6662(e) A. IRS's Penalty Assertion The IRS has asserted a 20% substantial valuation misstatement penalty under IRC § 6662(e) on the tax attributable to the $380,400,000 net § 482 allocation. Section 6662(e) imposes a 20% penalty on the portion of an underpayment of tax attributable to a substantial valuation misstatement under Chapter 1, which includes (among other things) any

VI. Assessment of IRS Economist's Methodology (Dr. Alan Washburne) A. PCT Valuation — Income Method As discussed in Section III.A above, Dr. Washburne valued the platform contribution transaction at $852,000,000 using an income method with a 7.2% weighted average cost of capital, compared to the $312,000,000 actually paid by PBI on July 1, 2012. The $540 million delta between the IRS's valuation and the actual PCT pa